ALPCO And InSphero Partner To Offer A Complete Solution To Assess Beta-Cell Function In Islet Microtissue Culture Models

ALPCO and InSphero announce partnership to provide customers with a complete solution to assess beta-cell function in islet microtissue culture models.

ALPCO, a leading producer of research and clinical immunoassays, recently announced its partnership with InSphero, AG to provide customers with a complete solution to assess beta-cell function in islet microtissue culture models. InSphero’s 3D InSight Diabetes Discovery Platformoffers users a comprehensive beta-cell function application suite with all required materials to quantify insulin secretion from 3D InSight Islet Microtissues, including ALPCO’s validated STELLUX Chemiluminescent Insulin ELISA.

“InSphero’s 3D InSight platform requires the use of highly sensitive assays that have a broad range and utilize a small sample size to accurately quantify the secretion of insulin and other beta-cell biomarkers from their precious islets,” explains ALPCO’s president, Sean Conley. “Through extensive testing, our STELLUX Chemiluminescent Insulin ELISA proved to meet or exceed the criteria needed for assaying islet microtissue cultures, demonstrating that it is a perfect fit for customers using 3D InSight.”

ALPCO and InSphero are also currently working to test and validate more STELLUX Chemiluminescent ELISAs to potentially include in the 3D InSight Diabetes Discovery Platform and further promote the advancement of early stage metabolic disease research.

For more information, visit alpco.com.